Bernd Bohrmann

9.1k total citations · 3 hit papers
58 papers, 6.6k citations indexed

About

Bernd Bohrmann is a scholar working on Molecular Biology, Physiology and Neurology. According to data from OpenAlex, Bernd Bohrmann has authored 58 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 25 papers in Physiology and 8 papers in Neurology. Recurrent topics in Bernd Bohrmann's work include Alzheimer's disease research and treatments (23 papers), Neuroinflammation and Neurodegeneration Mechanisms (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Bernd Bohrmann is often cited by papers focused on Alzheimer's disease research and treatments (23 papers), Neuroinflammation and Neurodegeneration Mechanisms (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Bernd Bohrmann collaborates with scholars based in Switzerland, Germany and United States. Bernd Bohrmann's co-authors include Heinz Döbeli, Marc Adrian, Christiane Ritter, David Schubert, Thorsten Lührs, Roland Riek, Ursula Rauch, Yale Nemerson, Jacques Himber and Juan J. Badimón and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Bernd Bohrmann

58 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

3D structure of Alzheimer's amyloid-β(1–42) fibrils

2005 1.8k citations Bernd Bohrmann, Heinz Döbeli et al. profile →
Blood-borne tissue factor: Another view of thrombosis

1999 772 citations Bernd Bohrmann et al. profile →
Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

2014 438 citations Jens Niewoehner, Bernd Bohrmann et al. Neuron profile →

Peers

Countries citing papers authored by Bernd Bohrmann

Since Specialization

Citations

This map shows the geographic impact of Bernd Bohrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Bohrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Bohrmann more than expected).

Fields of papers citing papers by Bernd Bohrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Bohrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Bohrmann. The network helps show where Bernd Bohrmann may publish in the future.

Co-authorship network of co-authors of Bernd Bohrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Bohrmann. A scholar is included among the top collaborators of Bernd Bohrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Bohrmann. Bernd Bohrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode 2018 ·Cell Reports ·Felix Weber, Bernd Bohrmann, Jens Niewoehner, Jens A. A. Fischer, Petra Rueger, Georg Tiefenthaler, (unknown), Alexander Bujotzek, Kevin Brady, Thomas P. Singer, Martin Ebeling, Antonio Iglesias, Per‐Ola Freskgård	66
2	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation 2018 ·Theranostics ·Matthias Brendel, Anna Jaworska, Felix Overhoff, Tanja Blume, Federico Probst, Franz‐Josef Gildehaus, Peter Bartenstein, Christian Haass, Bernd Bohrmann, Jochen Herms, Michael Willem, Axel Rominger	21
3	Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Edilio Borroni, Bernd Bohrmann, Fiona Grueninger, Eric Prinssen, Stephane Navé, Hansruedi Loetscher, Shankar J. Chinta, Subramanian Rajagopalan, Anand Rane, Almas Siddiqui, Bart Ellenbroek, (unknown), Axel Pähler, Julie K. Andersen, R. Wyler, Andrea M. Cesura	75
4	Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice 2017 ·Reproductive Toxicology ·Paul Barrow, (unknown), Alan M. Hoberman, Bernd Bohrmann, W. Richter, Christine M. Schubert	8
5	TREM2-deficiency reduces the efficacy of immunotherapeutic amyloid clearance 2016 ·Journal of Neurochemistry ·Xianyuan Xiang, Georg Werner, Bernd Bohrmann, Fargol Mazaheri, Anja Capell, Regina Feederle, Irène Knuesel, Gernot Kleinberger, Christian Haass	1
6	A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies 2016 ·Brain ·Aurélien Lathuilière, (unknown), Alberto Astolfo, Erhard Kopetzki, Helmut Jacobsen, Marco Stampanoni, Bernd Bohrmann, Bernard L. Schneider, Patrick Aebischer	34
7	TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance 2016 ·EMBO Molecular Medicine ·Xianyuan Xiang, Georg Werner, Bernd Bohrmann, Arthur Liesz, Fargol Mazaheri, Anja Capell, Regina Feederle, Irène Knuesel, Gernot Kleinberger, Christian Haass	128
8	Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APP_LondonMice 2014 ·Journal of Neuroscience ·Helmut Jacobsen, Laurence Ozmen, Antonello Caruso, Robert Narquizian, Hans Hilpert, Björn Jacobsen, Dick Terwel, (unknown), Bernd Bohrmann	68
9	Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle breakdown → 2014 ·Neuron ·Jens Niewoehner, Bernd Bohrmann, Ludovic Collin, Eduard Urich, Hadassah Sade, Peter Maier, Petra Rueger, Jan Olaf Stracke, Wilma Lau, Alain C. Tissot, Hansruedi Loetscher, Anirvan Ghosh, Per‐Ola Freskgård	438
10	Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7 2012 ·British Journal of Pharmacology ·Christoph Ullmer, Sannah Zoffmann, Bernd Bohrmann, Hugues Matile, Lothar Lindemann, (unknown), Pari Malherbe	20
11	Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice 2008 ·Behavioural Pharmacology ·Rebecca E. Nordquist, Hélène M. Savignac, Meike Pauly-Evers, Gaby Walker, (unknown), Edilio Borroni, (unknown), Bernd Bohrmann, Jürg Messer, Laurence Ozmen, (unknown), Will Spooren	12
12	Antiproliferative Activity of the Human IFN- α -Inducible Protein IFI44 2007 ·Journal of Interferon & Cytokine Research ·(unknown), (unknown), Martin Ebeling, Clemens Broger, (unknown), (unknown), Bernd Bohrmann, Ulrich Certa, Stefan Foser	84
13	High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain 2006 ·Neuroscience ·Andreas Güntert, Heinz Döbeli, Bernd Bohrmann	145
14	Acute Renal Effects of Intravenous Bisphosphonates in the Rat 2005 ·Basic & Clinical Pharmacology & Toxicology ·Thomas D. Pfister, (unknown), Bernd Bohrmann, Frieder Bauss	35
15	Quantification of the Aβ peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry 2005 ·Journal of Mass Spectrometry ·(unknown), Andreas Güntert, Bernd Bohrmann, Axel Ducret, Heinz Döbeli	38
16	Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis 2004 ·Current Vascular Pharmacology ·Christian Ihling, Bernd Bohrmann, Hans E. Schaefer, Katja Technau‐Ihling, Bettina Loeffler	21
17	Inhibition of proliferation by 1-8U in interferon-α-responsive and non-responsive cell lines 2003 ·Cellular and Molecular Life Sciences ·Reto Brem, (unknown), Stefan Foser, Bernd Bohrmann, Ulrich Certa	37
18	The Toxicity of the Alzheimer's β-Amyloid Peptide Correlates with a Distinct Fiber Morphology 1997 ·Journal of Structural Biology ·Bernd Seilheimer, Bernd Bohrmann, Luca Bondolfi, Francis Müller, Dietrich Stüber, Heinz Döbeli	191
19	Concentration evaluation of chromatin in unstained resin-embedded sections by means of low-dose ratio-contrast imaging in STEM 1993 ·Ultramicroscopy ·Bernd Bohrmann, Maximilian Haider, E. Kellenberger	68
20	In situ localization of the 60 k protein of Helicobacter pylori, which belongs to the family of heat shock proteins, by immuno-electron microscopy 1993 ·Zentralblatt für Bakteriologie ·(unknown), Bernd Bohrmann, (unknown), E. Schiltz, Manfred Kist	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact